Blink and you will miss out! SECURE TRIAL progress report (67Cu-Sar-bisPSMA dose escalation) - The Theranostics Study - Will drop any time - Recruitment plus details of patient mix - Enza combo data is keenly awaited
SABRE data readout (64Cu-Sar-BOMBESIN is PSMA negative Prostate Cancer) - Expected this or next month - Could there be some conference presentations? - And a plan for what happens next: P3 plans, etc - What does the FDA think of the data (i.e.: are we going for any of those statuses we love)?
DISCO data readout (64Cu-SARTATE in NETS) - We had a primer: Recruitment stopped at 45 instead ogf the planned 63, because we had the evidence of superiority early! - Expected this or next month - Could there be some conference presentations? - And a plan for what happens next: P3 plans, etc - What does the FDA think of the data (i.e.: are we going for any of those statuses we love)?
Co-PSMA progress report (64Cu-Sar-bisPSMA in Prostate CancerBiochemical Recurrence) - This is the Head to Head versus 68Ga-PSMA-11 (Illuccix equivalent) - No dates given so we can expect an announcement any time
CLARIFY TRIAL (64Cu-Sar-bisPSMA in Preprostatectomy Prostate Cancer) - Progress report keenly awaited - No dates given so we can expect an announcement any time
AMPLIFY TRIAL (64Cu-Sar-bisPSMA in BCR) - Progress report on the trial plans keenly awaited - We can expect an announcement any time: are we doing it, has it started, or?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)